Rest AP-Aripiprazole

From Psychiatrienet
Revision as of 11:12, 15 January 2013 by Musys (talk | contribs)
Jump to: navigation, search
Rest anti-psychotics

Chlorprothixene
Flupentixol
Loxapine
Pericyazine
Perphenazine
Trifluoperazine
Ziprasidone
Zuclopenthixol

Ariprazole
Type Antipsychotic
Group Atypical AP
Other use moodstabilizer
links
EMEA abilify
PubChem 60975
PubMed Ariprazole
Kompas (Dutch) Ariprazole
Wikipedia Ariprazole

Switch medication from Rest AP to Aripiprazole.[1] [2]
Rest AP is a collection of antipsychotic drugs having similar properties with respect to switching. A switch to member of the 'rest-AP' group from anotherdrug should be read as rest AP-anotherdrug. Similarly, a switch from a member of the 'rest-AP' group to anotherdrug should be read as anotherdrug-rest AP.

Nietinrijdenbord.png Stop Rest AP
  • Week 1-3: approx. 75% of initial dose
  • Week 4-6: approx. 50% of initial dose
  • Week 7-9: approx. 25% of initial dose
  • Week 10: stop
Eenrichtingbord.png Start Aripiprazole
  • Day 1: Start drug at target dose
Infobord.png More information
StartQuickDownweeks.jpg
Nietinrijdenbord.png — Rest AP
Eenrichtingbord.png — Aripiprazole


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.